Tumors grown in a stroma-rich mouse model resembling clinically advanced bladder carcinoma with UMUC3 and NIH 3T3 cells have high levels of fibroblasts and an accelerated tumor growth rate. We used this model to investigate the synergistic effect of combined gemcitabine monophosphate (GMP) nanoparticles and Cisplatin nanoparticles (Combo NP) on tumorassociated fibroblasts (TAFs). A single injection of Combo NP had synergistic anti-tumor effects while the same molar ratio of combined GMP and Cisplatin delivered as free drug (Combo Free) fell outside of the synergistic range. Combo NP nearly halted tumor growth with little evidence of general toxicity while Combo Free had only a modest inhibitory effect at 16 mg/kg GMP and 1.6 mg/kg Cisplatin. Combo NP increased levels of apoptosis within the tumor by approximately 1.3 fold (TUNEL analysis) and decreased α-SMA-positive fibroblast recruitment by more than 87% (immunofluorescence) after multiple injections compared with Combo Free, GMP NP or Cisplatin NP alone. The TAF-targeting capability of Combo NP was evaluated by double staining for TUNEL and α-SMA at various time points after a single injection. On day one after injection, 57% of the TUNEL-positive cells were identified as α-SMA-positive fibroblasts. By day four, tumor stroma was 85% depleted and 87% of the remaining TAFs were TUNEL-positive. Combo NP-treated tumors became 2.75 fold more permeable than those treated with Combo Free as measured by Evans Blue. We conclude that the antineoplastic effect of Combo NP works by first
Introduction
Bladder cancer, the fourth most common cancer diagnosed in men and the eighth in women, remains a concern due to its prevalence and tendency to progress and recur [1] [2] [3] . Advances in drug delivery are needed and nanomedicine in particular holds promise as a means to improve bioavailability and half-life in circulation [4, 5] . These therapies make use of the enhanced permeability and retention (EPR) effect in tumors, thereby increasing the chemotherapeutic dose to tumor tissue, while at the same time sparing normal tissue from exposure [6] . Improved drug uptake by tumor cells will also be an important consideration to achieve higher bioavailability.
Cancer has long been believed to be cell-autonomous and to date most research has focused directly on the malignant cells themselves. New data, however, suggests that carcinogenesis is determined not only by malignant cells, but also by a favorable tumor microenvironment [7] . Fibroblasts are the principal cellular component of the tumor microenvironment. Fibroblasts that have been recruited, activated and accumulated in close proximity to the tumor are referred to as tumor-associated fibroblasts (TAFs), myofibroblasts, or cancerassociated fibroblasts. In some instances, TAFs can be the most abundant type of cell within some tumors, notably pancreatic and breast carcinoma [8, 9] . These cells are characterized by high expression of α-smooth muscle actin (α-SMA). They contribute to tumor growth and invasiveness by remodeling the extracellular matrix, secreting various soluble factors (growth factors and cytokines), and suppressing immune responses. Normalization or elimination of activated stroma should be considered as a potential approach to anti-cancer therapy [10] . Therapies directed at TAFs can be divided into four categories: (1) inhibition of stromal cell proliferation; (2) interference with growth factor/cytokine-mediated signals between TAFs and cancer cells [11] ; (3) targeting of epigenetic alterations (DNA methylation); (4) modification of the inflammatory response [12] .
Myofibroblasts tend to be present in invasive bladder tumors and may be an individual prognostic factor in urothelial carcinoma [13] . To identify and test TAF-targeting drugs for treatment of bladder cancer, a model system is needed which reproduces the stroma-rich tumor growth observed in patients. Human tumor xenografts in immunodeficient mice are often used for preclinical studies of anti-cancer agents. A subcutaneous xenograft is most commonly used due to ease of implanting tumor cells and unobstructed access to the tumor. A major criticism of this model, however, is that the local environment may not adequately simulate the carcinoma microenvironment [14] . Here we report the establishment of a stroma-rich, subcutaneous xenograft tumor model. Fibroblasts were subcutaneously coinjected along with cancerous cells and Matrigel, a permissive extracellular matrix preparation. When grown on Matrigel in vivo, bladder carcinoma cells adopt a more characteristic phenotype [15] and the xenograft better resembles the original tumor when compared to the more commonly used model.
We recently developed nanoparticles for treatment of non-small-cell lung cancer that encapsulate gemcitabine monophosphate (GMP, the bioactive form of gemcitabine) [16] . We have also developed Cisplatin nanoparticles by mixing the highly soluble precursor cisdiaminodihydroplatinum (II) with KCl [17] . In both cases, high drug entrapment efficiency was achieved with NP diameters of approximately 45 nm and 40 nm for GMP NP and Cisplatin NP, respectively.
Our current work aimed to develop a stroma-rich, subcutaneous xenograft bladder tumor model for evaluation of TAF-targeting anti-tumor drugs. We planned to use this model system to evaluate GMP NP and Cisplatin NP combination therapy (Combo NP) in terms of delivery, accumulation of drug within the tumor, and anti-tumor activity. We also set out to investigate the TAF-targeting capability of Combo NP with TAFs apoptosis, collagen deposition and changes in tumor permeability evaluated.
Materials and Methods

Materials
Gemcitabine monophosphate disodium salt (GMP, purity≥97%) was provided by Qualiber, Inc. (Chapel Hill, NC). Cisplatin (cis-diamminedichloroplatinum (II)) was purchased from Sigma-Aldrich (Dorset, UK). GMP NP (including 3 H-labeled GMP NP) and Cisplatin NP were prepared as described previously [16, 17] . Size distribution and zeta potential were measured on a Malvern ZetaSizer Nano series (Westborough, MA).
The human bladder transitional cell line UMUC3 was from the American Type Culture Collection (ATCC), and the mouse embryonic fibroblast cell line NIH 3T3 (UNC Tissue Culture Facility) were cultured in Dulbecco's modified Eagle's Media (DMEM) (Invitrogen, Carlsbad, CA) supplemented with penicillin (100 U/mL) and streptomycin (100 µg/mL) (Invitrogen), and 10% fetal bovine serum (Sigma, St. Louis, MO)/10% Bovine calf serum (Hyclone, Logan, Utah), respectively. Cells were cultivated in a humidified incubator at 37°C and 5% CO 2 and harvested with 0.05% trypsin-EDTA before subculture.
Female nude mice 6-8 weeks of age were used in all studies. All work performed on animals was approved by the Institutional Animal Care and Use Committee at University of North Carolina at Chapel Hill.
Stroma-rich subcutaneous xenograft bladder tumor model
To establish the xenograft model, UMUC3 (5×10 6 ) and NIH 3T3 cells (2×10 6 ) in 100 µL of PBS were subcutaneously co-injected with Matrigel (BD Biosciences, CA) at a ratio of 1:1 (v/v) into the right flank of mice. For the standard subcutaneous bladder tumor model, only UMUC3 cells (5×10 6 ) were injected. Tumor volume was measured every three days starting on day seven after inoculation. 
Tumor accumulation of GMP and Cisplatin in established animal model
To measure tumor accumulation of Combo Free and Combo NP, animals were randomly divided into two groups (n=6) and intravenously injected with free GMP containing a tiny fraction of 3 H-Labeled free cytidine monophosphate, which is believed to have the similar pharmacokinetic profile as GMP [16] and Cisplatin (Combo Free) and Combo NP at a dose of 16 mg/kg and 1.6 mg/kg respectively. Three mice from each group were sacrificed at each predestinate time point, and approximately 45 mg of blood was withdrawn using the tail bleeding method. Tumor uptake of GMP and Cisplatin was expressed as the percentage of the injected dose per gram tumor. For measurement of GMP, 10 to 20 mg of blood was immediately mixed with 10× NCS ® II Tissue Solubilizer (Amersham Biosciences, Inc) and digested at 60°C overnight. Three hundred µL of hydrogen peroxide (30% in water, Fisher) was added to the samples and vortexed to bleach the blood color, and then the sample was mixed with 4 mL scintillation cocktail (Fisher Inc). The 3 H radioactivity in the blood samples was counted using a liquid scintillation analyzer (TRI-CARB 2900 TR, Packard Bioscience Co.). For the measurement of Cisplatin, approximately 30 mg of blood was digested with 400 µL 60% nitric acid (Acros Organic) at 70°C overnight and measured by Inductively Coupled Plasma-Mass Spectroscopy (ICP-MS, NexIONTM 300, Perkin Elmer Inc).
Anti-tumor efficacy in stroma-rich xenograft bladder tumor model
On day seven after implantation, mice were randomized by completely randomized design using a random number table into seven groups (n=5) as follows: Saline (Control group), free GMP (GMP Free), free Cisplatin (Cisplatin Free), combination of free GMP and Cisplatin (Combo Free), GMP NP, Cisplatin NP and combination of GMP NP and Cisplatin NP (Combo NP). For combination of free drugs or nanoparticles, free drugs or nanoparticles were mixed right before injection. Once they are mixed, the mixture was injected intravenously. IV injections were performed every three days for a total of 3 injections with the GMP dose at 16 mg/kg and Cisplatin at 1.6 mg/kg. Tumor volume was measured every three days using the aforementioned method. Body weight was also recorded. Mice were sacrificed two days after the last injection by CO 2 asphyxiation and tumors were excised. A portion of the tumor was fixed in 10% formalin and paraffin-embedded sectioned for H&E staining, TUNEL assay, and α-SMA immunofluorescence by an operator blinded to the treatment groups.
In vivo toxicity analysis
After three daily injections, blood was collected from the venous plexus of the eye and centrifuged at 4,000 rpm for 5 min. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine levels were assayed as indicators of hepatic and renal function. Organs (heart, liver, spleen, lung, kidney) were fixed and sectioned for H&E staining.
Tissue analysis
Tumor sections were stained for TUNEL assays as recommended by the manufacturer (Promega, Madison, WI). DAPI mounting medium was dropped on the sections for nuclear staining. Apoptosis was also determined by H&E staining. Tumors were also prepared for α-SMA immunofluorescence (FITC label). Images were acquired by an Eclipse Ti-U inverted microscope (Nikon Corp., Tokyo, Japan) at 20× magnification and analyzed on Image J (National Institutes of Health).
TAF-targeting efficacy in stroma-rich xenograft bladder tumor model
Mice with 200 mm 3 tumors were treated with a single dose of Combo NP (GMP 16 mg/kg, Cisplatin 1.6 mg/kg) (n=24). Every 24 hours, mice were sacrificed. Tumors were excised and sectioned for α-SMA (Alaxa Fluor 647)/TUNEL immunofluorescence double staining and Masson's trichrome (Sigma, USA).
Analysis of tumor permeability
Drug permeability in the tumor was evaluated by Evans Blue assay [20] . Tumor-bearing mice were randomized into three groups (n=3) as follows: Control group, Combo Free and Combo NP. Single intravenous injection was performed for each treatment with the GMP dose at 16 mg/kg and Cisplatin at 1.6 mg/kg. Twenty-four hours later, 100 mg/kg of Evans Blue (10 mg/ml in 0.9% NaCl) was intravenously injected. After 30 min, mice were sacrificed and blood and tumor tissue were homogenized in a 0.1% sodium sulfate/acetone mixture (7:3 v/v) at a ratio of 1:9. Samples were maintained at ambient temperature in the dark overnight and then centrifuged at 1,000 g for 5 min. Supernatants were used to determine absorbance at 620 nm. The amount of Evans Blue in tumor tissue was expressed as µg/g tissue.
Statistical analysis
Results were expressed as a mean±standard deviation (S.D.). Student's t-test and one-way analysis of variance (ANOVA) test were used to evaluate statistical significance. A p value of p<0.05 was considered to indicate statistical significance.
Results and discussion
Characterization of GMP NP and Cisplatin NP
The dioleoylphosphatydic acid (DOPA) was employed as a pre-coating reagent for the nanosized CaP cores. The lipid coating prevents the core from aggregation during the centrifugal separation step and makes it soluble in chloroform. The DOPA layer coating CaP core served as the inner leaflet lipid and a variety of lipids for the outer leaflet could simply be added into the CaP core solution in chloroform. The choice of the asymmetric outer lipids plays an important role in the pharmacokinetics and tissue distribution of the final nanoparticles [21] . Asymmetric lipid bilayer-modified nanoparticles for GMP and Cisplatin were prepared as previously reported [16, 17] . Particles with a core-shell shape were 44.5±0.2 nm and 40.6±0.2 nm for GMP NP and Cisplatin NP, respectively. Particles exhibited high entrapment efficiency at around 49.5% and 44%, and zeta potential of 11.5±0.6 mV and 5.6 ±0.3 mV for GMP NP and Cisplatin NP, respectively. The drug loading was 23±2 wt % (n=3) and 82±5 wt % (n=3) for GMP NP and Cisplatin NP, respectively (Fig. S1 ).
Histopathology for stroma-rich subcutaneous xenograft bladder tumor model
Xenografts with UMUC3 and/or NIH 3T3 cells and patient tumor sections were stained with H&E and for α-SMA (FITC labeled). Our tumor model was enriched with stroma structure (H&E) and α-SMA positive cells (17.5±3.2%, UMUC3/NIH 3T3) compared to the common subcutaneous bladder model with injection of UMUC3 cells alone (1.8±0.6%, UMUC3), and more closely resembles human bladder tumor structure (14.8±2.1%, Patient) (Fig. 1A) . Alpha-SMA-positive fibroblasts co-located with CD31-positive blood vessel endothelial cells in our established tumor model (Fig. 1B) . The stroma-rich tumor (co-injection with UMUC3 and NIH 3T3 cells) grew more rapidly (Fig. 1C) .
No tumor growth was observed if only NIH 3T3 cells were inoculated. Therefore, such a stroma-rich tumor closely mimics the structure of human bladder cancer isolates, which should enable us to better understand the synergistic effect of Combo NP on tumor inhibition and TAF-targeting effect.
Synergistic effect induced by tumor accumulation of GMP NP and Cisplatin NP
Gemcitabine has been reported to affect the expression of key proteins involved in nucleotide excision repair (NER) and mismatch repair (MMR), thereby inhibiting repair of DNA damage caused by Cisplatin [22] . Synergy between gemcitabine and Cisplatin might be related to the reduced DNA repair of intra-strand and possibly inter-strand cross-links of Cisplatin [23] . In vitro toxicity analysis of combined GMP and Cisplatin was performed after 48 h treatment of UMUC3 cells (Fig. 2) . The combination index (CI) was calculated using a series of molar ratios and amounts of GMP and Cisplatin. CI values were analyzed according to Chou and Talalay [18] using CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA). The CI fell between 0.1 and 0.3 over a broad range of drug ratios from the CI vs Fa plot (Fig. 2B) . Synergy, as indicated by a CI<1, therefore, is assumed to be induced over a wide range of free drug ratios. Within the range of drug ratios, the synergistic effect of GMP and Cisplatin at a molar ratio of 10 to 1, not only as free drugs but also in nanoparticles, was further affirmed by in vitro cytotoxicity study of GMP NP, Cisplatin NP, and Combo NP (Fig. S2) . The combination of GMP NP and Cisplatin NP (molar ratio of 10:1) was indicated to exhibit better performance than single nanoparticles alone over a range of concentrations with the lowest IC 50 and small CI value under one. According to the in vitro data for free drugs and nanoparticles, we apply the combination of GMP NP and Cisplatin NP at synergistic ratio for further in vivo experiments.
Next, we investigated the synergistic effect of Combo NP and Combo Free in vivo. The resulting pharmacokinetics (Fig. S3) suggests that Combo NP provides advantages over Combo Free. About 40 to 45% of the GMP NP were retained in the blood circulation 2 h after bolus administration, while the free GMP was rapidly cleared within 20 min. AUC and half-life of Cisplatin NP were 1.4 to 1.7 times higher than that of Cisplatin Free, for which more than 80% had been cleared after the first 20 min. Incorporation of GMP and Cisplatin in lipid bilayer coated nanoparticles modified with hydrophilic polyethylene glycol increased the drug retention in the circulation and reduced the drug clearance which is consistent with our previous pharmacokinetic studies [16] . However, there is significant discrepancy in the PK profile of GMP NP and Cisplatin NP. One explanation for the difference is that GMP NP with highly positive charges (11.5 mV) are more likely to bind with serum proteins, leading to longer circulation in the system but lower tissue distribution; however, Cisplatin NP with relatively neutral charges (5.6 mV) worked in the opposite way. Moreover, Cisplatin NP produced a slightly higher accumulation in tumor than GMP NP after a single injection. Both nanoparticles showed significantly higher tumor accumulation (more than 10% of injected dose per gram remained in the tumor 10 h post injection) than the free drugs (less than 2% of injected dose per gram left 10 h post injection) (Fig. 2C) . One possible reason is the phenomenon known as enhanced permeability and retention (EPR). The vasculature of tumors is comprised of poorly aligned and defective endothelial cells lacking innervation [24, 25] . Nanoparticle formulations can increase tumor accumulation through the EPR effect and with a specific targeting ligand can enhance tumor cell uptake through a receptor mediated pathway.
The ratio of GMP to Cisplatin (mol: mol) in tumor after Combo NP injection, which is in the wide synergistic range of free drugs (Fig. 2B ) was 8.35:1, and 6.75:1 at 5 h and 10 h after injection (Fig. 2C) ; therefore, a synergistic effect took place. When taken together and incorporated into nanoparticles, GMP and Cisplatin exhibited increased drug retention in the circulation and enhanced tumor accumulation without altering the synergy. This may result in more potent anti-tumor effects and reduced side effects [26, 27] .
Anti-tumor effect of combined therapy
Here, we report the potent anti-tumor efficacy of the Combo NP in our stroma-rich bladder tumor model at a dose of 16 mg/kg for GMP and 1.6 mg/kg for Cisplatin. We first determined whether Combo NP can exhibit synergistic anti-tumor effects without significant adverse effects (Fig. 3) .
When treatment began on day seven after inoculation, free Cisplatin (1.6 mg/kg) monotherapy showed little anti-tumor effect, with Cisplatin NP being more effective than free drug (p<0.05). Tumor growth was delayed significantly in mice treated with free GMP and GMP NP compared to the control group after multiple doses. In comparison, Combo NP treated tumors had significantly smaller volume than the other six groups at the end of the experiment, showing growth of only 0.3 fold more than the day one tumor volume. No weight loss was observed in any treatment group, indicating that the treatment was well tolerated (data not shown). The enhanced tumor growth inhibition exhibited by nanoparticles should be attributed to the endocytosis mediated by the sigma receptors and EPR effect [28] , which is also indicated by the tumor accumulation study aforementioned. Nanoparticle formulation with specific targeting ligand can increase tumor accumulation through EPR effect and enhanced tumor cell uptake through receptor-mediated pathway. Furthermore, in vivo maintenance of drug ratios shown to be synergistic in vitro was proven to provide increased efficacy in preclinical tumor models [29] . Therefore, the synergistic effect proven by the tumor accumulation study (Fig. 2) , enabled the Combo NP to show the most outstanding effect on tumor growth inhibition in comparison with GMP NP and Cisplatin NP alone.
In vivo toxicity
To test the toxicity of combined GMP NP and Cisplatin NP, blood was obtained for hematological analysis and histopathology of organs was evaluated by H&E staining. Gemcitabine and Cisplatin are notable for their potential hepatic and renal toxicities respectively. In our toxicity studies, AST increased slightly in Combo NP group, but remained within the normal range (Table 1 ) [16] . No noticeable histological changes were seen in H&E-stained tissue sections of heart, liver, spleen, lung and kidney (Fig. S4 ). There were no noticeable changes between the control and Combo NP group, which showed no evidence of organ toxicity. These findings suggest the potential application of nanoparticles in clinic.
Combo NP triggers cell apoptosis and inhibits fibroblasts growth
Stroma-rich tumor-bearing mice were sacrificed two days after the final injection and the tumors were sectioned for TUNEL assay and α-SMA immunohistochemistry. In the TUNEL assay (Fig. 4A) , the Combo NP exhibited the most effective killing effects and induced a 16.1 fold higher amount of apoptotic cells compared with the control group. This was more potent than the Combo Free treatment group, which showed 55.5% less apoptosis than that of the Combo NP. There was no significant difference among Combo Free, GMP NP and Cisplatin NP groups (p>0.05). Cisplatin Free treatment had limited ability to induce apoptosis in tumor cells. The results indicate the combination of GMP NP and Cisplatin NP augments the intrinsic cytotoxicity. This finding is consistent with data in Figure 3 that the Combo NP exerts synergistic anti-tumor effects.
Meanwhile, Combo NP not only elicited an apoptosis-inducing effect on carcinoma cells, but also changed the number of α-SMA-positive fibroblasts in the tumor extracellular matrix. To assay for this change, we used immunofluorescence to measure the percentage of α-SMA-positive fibroblasts in the normal untreated tumor and in tumors treated with different preparations (Fig. 4) . α-SMA was significantly decreased in the Combo NP group compared to the untreated group (0.7±0.3% vs. 17.6±3.2%, percentage of positive-stained cells, p<0.05). The fibroblasts expression after Combo NP treatment was 89.7%, 87.2% and 94.3% lower than that after GMP Combo NP 58.3±6.8 252±10.3 5.3±0.4 0.2±0.1 NP, Cisplatin NP, and Combo Free treatment, respectively (p<0.05). Those results suggest the importance of the combination of GMP NP and Cisplatin NP for in vivo efficacy. H&E staining also indicated that the Combo NP caused the most severe necrosis in the tumor.
Combo NP depletes TAFs in the tumor, modifies collagen deposition
Taking advantage of the stroma-rich animal model, the interaction of TAFs and the combined drugs was also investigated. The effect of a single Combo NP injection treatment on fibroblasts and tumor cells in the stroma-rich bladder tumor model was investigated from day one to day seven after treatment. Day 0 before treatment was also investigated. Firstly, 4.9% of cells were induced to undergo apoptosis one day after Combo NP injection, among which 56.6% apoptotic cells were α-SMA-positive. This suggests that the fibroblasts have a greater tendency to be killed compared to tumor cells. From day one to day two, the apoptotic fibroblasts in total apoptotic cells increased dramatically resulting in more than 60% apoptotic fibroblasts. The apoptotic cells in fibroblasts reached 87.2% on day four, which was 45% higher than that in carcinoma cells. The results indicate that the apoptosis of fibroblasts not only began before that of carcinoma cells but also substantially resulted in fibroblast depletion. By the last two days, the killing effect of the Combo NP was reduced and fewer cells were apoptotic, with the increasing number of α-SMA-positive fibroblasts. Therefore, the apoptotic fibroblast (%) in total fibroblast was significantly decreased to nearly 1%. Secondly, the collagen on day four became 14.9% of the original collagen present on day 0, a value also different from that of day three. This shows that the killing effect of Combo NP on TAFs in the first three days resulted in the decreased deposition of collagen on day four. Collage deposition showed an increasing trend starting on day five (Fig. 5D) .
As it is shown in Fig. 4 , Combo Free, GMP NP, and Cisplatin NP exhibited partial efficacy in reducing fibroblasts, but Combo NP showed the fewest α-SMA positive cells and induced the most tumor cell apoptosis compared to all the treatment groups (p<0.05). The data suggest that the combination therapy may have a TAF-targeted effect by inducing cell apoptosis with a strong inhibition of stroma cell proliferation. Under that hypothesis, we administered a single injection of Combo NP and detected the apoptotic fibroblasts every 24 h after injection. The larger amount of apoptotic fibroblasts compared to apoptotic tumor cells and collagen re-deposition indicated that tumor stroma was the target for the Combo NP and tumor cell killing could be the secondary role of the Combo NP. The TAF-targeting effect could be interpreted by the following two explanations: (1) the myofibroblasts were much more sensitive to the Combo NP than that of bladder carcinoma cells. (2) Tumor blood vessels are reported to be located in the stroma [30, 31] and Fig. 1B also indicates that some CD31-positive cells are co-located with α-SMA-positive fibroblasts. Our explanation could be that Combo NP, once delivered through tumor vessels and transferred from the vessel wall with high permeability through extra cellular matrix to the tumor cells will exhibit killing effect on the TAFs as the first target instead of tumor cells since the TAFs are distributed along the vessel or near the vessel.
Tumor vessel permeability
Passive targeting of liposomal formulations is mediated mainly by the enhanced vascular permeability of tumor vessels. To evaluate vascular permeability after Combo Free and Combo NP treatment, tumor bearing mice were intravenously injected with Evans Blue, which binds to serum albumin and tends to accumulate in tissues with leaky vasculature [20] . Vascular permeability was found to be nearly 21.3 and 2.7 times higher in the Combo NP group than in the Control and Combo Free groups, respectively (Fig. 6 ). Besides the increasing transport through vasculature, the enhanced intratumoral uptake of Evans Blue might also be contributed to tumor priming effect by substantial apoptosis caused by pretreatment with single injection of Combo NP (Fig. 5 ). This could reduce tumor cell density, expend the interstitial space and then promote the penetration into threedimensional tumor histocultures [32, 33] . Further investigation is desired for the mechanism of greater tumor uptake of Evans Blue.
The more pronounced accumulation from Combo NP could be attributed to the synergistic effect of GMP NP and Cisplatin NP on the tumor blood vessels: (1) Combo NP could significantly reduce the expression of vascular endothelial growth factor (VEGF) (Fig. S5) , which is an important mediator of tumor angiogenesis, and enhance the extent of tumor vasculature abnormalities, which impairs the tumor growth [34] [35] [36] . This finding is consistent with previous result that Combo NP exerts higher tumor inhibition (Fig. 3) ; (2) Fig. 5 indicates that because of their sensitivity or proximity to tumor blood vessels, the TAFs will be first killed by nanoparticles distributed in the stoma and the collagen in stroma will be depleted. This depleting effect could be helpful for better distribution of antitumor compounds in the tumor area which would not otherwise access the tumor cells [37] , and enhance the total drug tumor accumulation and transport to carcinoma cells.
Conclusions
In this study, anti-tumor effects of Combo NP were investigated in a stroma-rich xenograft bladder cancer model. GMP and Cisplatin accumulated in treated tumor tissue at a molar ratio and concentration expected to have synergistic anti-tumor effects. Combo NP's ability to inhibit tumor growth was enhanced relative to Combo Free with no obvious toxicity. The effectiveness of Combo NP could be attributed to its effect on both carcinoma cells and TAFs. The anti-tumor activity of Combo NP may result from the combined effects of TAFs depletion with alterations in collagen deposition and increased uptake of chemotherapeutic drugs by the tumor and apoptosis of carcinoma cells. Since the standard first line chemotherapy for muscle invasive bladder cancer is now gemcitabine plus Cisplatin [38, 39] , the result of our study suggest that Combo NPs could be tested clinically to replace free drug combination.
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